Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -4,7 +4,7 @@
4	4
5	5	= Overview =
6	6
7		-Vascular Biogenics (VBLT) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company conduct business under the name VBL Therapeutics. Vascular Biogenics was incorporated in Israel on January 27, 2000 as a company limited by shares under the name Medicard Ltd. In January 2003, the company changed its name to Vascular Biogenics Ltd. The company's program is based on its proprietary Vascular Targeting System, or VTS, platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels, and which the company believe will allow it to develop product candidates for multiple oncology indications.{{footnote}}https://fintel.io/doc/sec/1603207/000149315218003377/form20-f.htm{{/footnote}}
	7	+Vascular Biogenics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company conduct business under the name VBL Therapeutics. Vascular Biogenics was incorporated in Israel on January 27, 2000 as a company limited by shares under the name Medicard Ltd. In January 2003, the company changed its name to Vascular Biogenics Ltd. The company's program is based on its proprietary Vascular Targeting System, or VTS, platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels, and which the company believe will allow it to develop product candidates for multiple oncology indications.
8	8
9	9	The company's lead product candidate, VB-111 (ofranergene obadenovec), is a gene-based biologic that Vascular Biogenics is developing for solid tumor indications, and which Vascular Biogenics has advanced to programs for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer, ovarian cancer and thyroid cancer. Vascular Biogenics has obtained fast track designation for VB-111 in the United States for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. Vascular Biogenics has also received orphan drug designation for GBM in both the United States and Europe. VB-111 has also received an orphan designation for the treatment of ovarian cancer by the European Medicines Agency. In September 2015, the company reported complete results from its Phase 2 trial of VB-111 in rGBM, demonstrating a statistically-significant benefit in overall survival and favorable response rate in patients treated with VB-111 in combination with bevacizumab. The company's pivotal Phase 3 GLOBE study in rGBM began in August 2015 and was comparing a combination of VB-111 and bevacizumab to bevacizumab alone. The study, which enrolled a total of 256 patients in the US, Canada and Israel was conducted under a special protocol assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA, with full endorsement by the Canadian Brain Tumor Consortium (CBTC). On March 8, 2018, the company announced top-line results from the GLOBE study, which showed that the study did not meet its pre-specified primary endpoint of overall survival (OS). No new safety concerns associated with VB-111 have been identified in the GLOBE study. Once the company receive the full and final data set, the company will conduct an in-depth analysis in order to better understand the outcome of the GLOBE study and the potential activity of VB-111 in rGBM. The company do not think that results of the GLOBE study in rGBM will necessarily have implications on the prospects for VB-111 in other tumor types. The company's OVAL phase 3 potential registration study of VB-111 in platinum resistant ovarian cancer was launched in December 2017 and is conducted in collaboration with the GOG Foundation, Inc., a leading organization for research excellence in the field of gynecologic malignancies.
10	10
...	...	@@ -28,7 +28,7 @@
28	28
29	29	Based on support from pre-clinical data, which the company presented at the American Society of Gene & Cell Therapy (ASGCT) conference in May 2017, the company planned to launch an exploratory study for VB-111 in combination with nivolumab, a checkpoint inhibitor, in non-small cell lung cancer. However, given the readout of the GLOBE trial, before the company launch such study, or studies, the company intend to conduct additional data analyses and revisit its clinical plans regarding new indications to seek the best way to advance VB-111 towards commercialization.
30	30
31		-= Strategy =
	31	+==== Strategy ====
32	32
33	33	The company's goal is to become a leading biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics that leverage its proprietary technologies for oncology indications. The company intend to achieve this goal by pursuing the following strategies:
34	34
...	...	@@ -227,5 +227,3 @@
227	227	The company's corporate headquarters and research facilities are currently located in Modi’in, Israel, where the company lease an aggregate of approximately 21,500 square feet of office and laboratory space, pursuant to a lease agreement that expires in June 2023. This facility additionally houses its clinical development, clinical operations, regulatory and management functions, as well as its local biological drugs manufacturing facility.
228	228
229	229	= References =
230		-
231		-{{putFootnotes/}}